Vor Biopharma Inc. (VOR) Stock

Vor Biopharma Inc. (VOR) is a Healthcare stock trading at $23.07 (as of 2026-08-20), with a market capitalization of $1.25B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Understand Vor Biopharma Inc.: how it makes money

Vor Biopharma develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients, including VOR33 for acute myeloid leukemia (AML), and it aims to generate value through successful clinical development and downstream collaboration or commercialization if the therapies prove safe and effective.

As a clinical-stage cell therapy developer, its profit model depends on turning trial evidence for its engineered stem cell approach (for example, CD33-negative eHSCs for AML) into regulatory approval and, potentially, partnership or commercialization revenues.

Business quality (Solid): No revenue reported and results are still being demonstrated through operational trial metrics, so the key question is whether early engraftment and editing outcomes for VOR33 translate into durable, clinically meaningful patient outcomes.

Bull case

Robust early engraftment signal: The Primary Neutrophil Engraftment Rate is 100.0%, with Median Time to Primary Neutrophil Engraftment of 9.5.
CD33 editing performance appears strong: Median CD33 Editing Efficiency is 90.0% (with Average CD33 Deletion Efficiency of 87.0%), aligning with the therapy design that lacks CD33 to target AML blood cancer cells.
Active clinical activity with measurable follow-up: Number of Patients Treated with Trem-cel is 25.0, and Median Follow-Up Duration is 7.4.

Bear case

Early-stage evidence, limited time horizon: Median Follow-Up Duration is 7.4, which may not fully capture durability of benefit or longer-term risks.
Smaller treated populations for key subgroups: Number of Patients Treated with Trem-cel Who Received Mylotarg is 15.0, so subgroup conclusions may be constrained by sample size.
No revenue yet, heavy operating losses: Revenue is 0.0 (for the latest period provided) and operating margin is -893.5, reflecting a burn profile typical of pre-commercial stage development.

Valuation — source: SEC EDGAR (first-party)
Price	$23.07
Market Cap	$1.25B
Price / Sales	89.65
FCF Yield	-20.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$5.87M
Net Margin	-11860.6%
Revenue Growth (YoY)	37.4%
EPS Growth (YoY)	4047.1%
FCF Growth (YoY)	43.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-3.91 (distress)

Valuation vs Sector & Industry
Sector P/E (Healthcare)	21.6
Industry P/E (Pharmaceutical Products)	17.2

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	TCG Crossover Management, LLC ($96.50M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Jean-Paul Kress
Employees	159
Country	US
IPO Date	2021-02-05

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.